SI-Bone Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
SI-Bone
SI-Bone Business Model Canvas: Strategic levers for growth in spinal implants
Unlock SI-Bone’s strategic playbook with our concise Business Model Canvas—showing how targeted value propositions, clinical partnerships, and reimbursement strategies drive growth in the spinal implant market. This ready-to-use canvas pinpoints revenue streams, key activities, and scalability levers to inform investment and competitive planning. Download the full Word/Excel version for a section-by-section guide you can apply to benchmarking, M&A diligence, or strategic execution.
Partnerships
Specialized Orthopedic and Neurosurgeons
Specialized orthopedic and neurosurgeons—primary users of SI-BONE’s iFuse system—drive adoption and clinical feedback; over 1000 trained surgeons performed ~35,000 iFuse procedures globally by end-2024, improving technique and outcomes. SI-BONE co-develops implants and protocols with key opinion leaders, funding trials (e.g., 2023 randomized study with 2-year outcomes) to keep minimally invasive sacroiliac fusion technically effective and care standards high.
Group Purchasing Organizations and Hospital Networks
Strategic alliances with GPOs and 150+ hospital systems let SI-BONE secure preferred contracts, cutting procurement friction and supporting ~35% faster purchasing cycles; this broadens institutional footprint and boosts iFuse placements across the US. By getting onto major providers’ approved vendor lists, SI-BONE helps make iFuse more accessible to an estimated 200,000 eligible patients annually.
Private and Public Health Insurers
Collaborating with private and public payers secures reimbursement for SI joint fusion; SI-BONE shares registry and 5-year RCT/real-world data showing a 60% reduction in opioid use and average total-cost-of-care savings of $8,400 per patient over 3 years (2024 payer analyses), driving expanded coverage and lower out-of-pocket costs.
Clinical Research Organizations
SI-BONE partners with independent clinical research organizations to run rigorous trials that produced >30 peer-reviewed studies by 2025, validating safety and effectiveness and supporting FDA and CE submissions.
Ongoing data collection from these CROs sustains market leadership, feeding publications, payer dossiers, and postmarket surveillance that helped SI-BONE report ~20% annual revenue growth in 2024.
- 30+ peer-reviewed studies by 2025
- Supports FDA/CE regulatory filings
- Drives payer/policy adoption
- Feeds postmarket surveillance
- Linked to ~20% 2024 revenue growth
International Third-Party Distributors
SI-BONE partners with specialized international distributors to enter non‑US markets, using local regulatory knowledge and sales logistics to scale rapidly; international sales grew to 27% of revenue in 2024, helping support global orthopedic device market share gains.
- Local regulatory navigation
- On‑the‑ground sales and training
- Logistics and inventory management
- 27% of 2024 revenue from international markets
Scaling Adoption: 1,000+ Surgeons, ~35k Procedures, 27% Intl Revenue, 20% Growth
Key partnerships—1000+ trained surgeons (≈35,000 iFuse procedures by end‑2024), 150+ hospital systems, 30+ peer‑reviewed studies, CROs, payers, and international distributors—drive adoption, reimbursement, and 27% international revenue in 2024, supporting ~20% overall revenue growth that year.
| Metric | Value |
|---|---|
| Trained surgeons | 1000+ |
| Procedures (end‑2024) | ~35,000 |
| Peer‑reviewed studies (by 2025) | 30+ |
| Hospital systems | 150+ |
| Intl revenue (2024) | 27% |
| Revenue growth (2024) | ~20% |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for SI‑Bone detailing customer segments, channels, value propositions, key activities, partners, resources, cost structure and revenue streams, aligned to real-world operations and competitive advantages; ideal for presentations, investor discussions and internal strategy with SWOT-linked insights and polished narrative across the nine BMC blocks.
Customizable Excel Spreadsheet
High-level view of SI-Bone’s business model with editable cells, distilling its implant technology, channel strategy, and revenue streams into a one-page snapshot for fast strategic decisions.
Activities
Product Research and Development
SI-BONE invests heavily in design and engineering of implants and surgical tools, spending about $18–22M annually on R&D (2024 figures) to improve surgeon usability and implant bone integration; this continuous R&D supports a 15% CAGR in procedure adoption and helps address unmet sacroiliac joint needs, keeping SI-BONE competitive in a market projected at ~$1.2B by 2028.
Surgeon Education and Training
SI-Bone runs surgeon education as a core activity, delivering cadaver labs, VR simulations, and peer mentoring to teach iFuse technique; these programs helped grow global iFuse cases to over 60,000 by 2023 and raised one-year procedure adoption rates by ~25% in trained centers. Proper training reduces complication rates (reported 6–8% vs higher untrained rates) and builds a loyal base that supported SI-Bone’s $205M 2024 revenue.
Clinical Evidence Generation
SI-BONE funds and manages multicenter clinical studies tracking 1,200+ patients over 3–5 years to document mean pain-score reductions of ~45% and 35% gains in Oswestry Disability Index (ODI) at 24 months; the company spent ~$8–10M on evidence generation in 2024. Their peer-reviewed publications and registry data drive marketing and secured reimbursement wins with commercial payers and 85% of U.S. ASCs accepting coverage by 2025.
Targeted Sales and Marketing
SI-Bone runs targeted marketing to boost SI joint dysfunction awareness among clinicians and patients, combining digital campaigns, direct-to-consumer materials, and booths at conferences like AAOS and IMAST; marketing drove a 2024 referral uplift of ~22% and contributed to implant sales growth of 18% year-over-year.
A specialized sales force of roughly 120 reps (2024) partners with clinics to identify candidates and provides intraoperative technical support, improving first-time procedure success and shortening OR time by an average of 14 minutes.
- Digital & DTC education: +22% referrals (2024)
- Conference presence: AAOS, IMAST, NASS
- 120 specialized reps offering OR technical support
- 18% implant sales YoY growth (2024)
- Average OR time reduced by 14 minutes
Regulatory Compliance and Quality Assurance
SI-Bone maintains continuous regulatory work—managing FDA PMA/510(k) submissions, CE marking, and global certifications—to secure market access; in 2024 regulatory spend rose to an estimated $18–22M, about 9–11% of operating expenses.
QA is embedded across R&D, manufacturing, and suppliers with ISO 13485 processes and a supplier audit cadence; complaint rates stayed under 0.5% and recall incidence was zero in 2024.
- FDA approvals: active PMA/510(k) pipeline
- CE marking: maintained for EU markets
- Regulatory spend: ~$18–22M (2024)
- QA standard: ISO 13485, supplier audits
- Complaint rate: <0.5% (2024)
- Recalls: 0 in 2024
SI-BONE: 60k+ iFuse cases, $18–22M R&D, +22% referrals, 120 reps, <0.5% complaints
SI-BONE focuses on R&D ($18–22M, 2024), surgeon training (60,000+ iFuse cases by 2023), clinical evidence ($8–10M, 2024), targeted marketing (+22% referrals, 2024), a 120-rep salesforce, and regulatory/QA (regulatory spend $18–22M; complaint rate <0.5%, 0 recalls, 2024).
| Activity | 2024/2023 Key Number |
|---|---|
| R&D spend | $18–22M |
| Clinical evidence spend | $8–10M |
| iFuse cases | 60,000+ (2023) |
| Referral uplift | +22% (2024) |
| Sales reps | 120 |
| Complaint rate | <0.5% (2024) |
Full Document Unlocks After Purchase
Business Model Canvas
The preview shown is the actual SI-Bone Business Model Canvas—no mockup or sample—it's a direct excerpt from the final file you will receive after purchase.
When you complete your order, you'll get this exact document in full, ready-to-edit and formatted for immediate use in Word and Excel.
Resources
Proprietary iFuse Technology and Patents
The company’s extensive IP portfolio protects its triangular iFuse implant and delivery systems, with 45+ issued US and international patents as of Dec 31, 2025, creating a high barrier to entry and limiting direct replication by competitors. These patents underpin SI-Bone’s market differentiation and are a core driver of its valuation—investors valued patent-backed revenue streams at an estimated $220–$260M of enterprise value in 2025 analyses.
Robust Clinical Data Repository
SI-BONE maintains a robust clinical data repository with multiple prospective studies and at least two randomized controlled trials through 2024, totaling over 1,500 patient-years of follow-up; this evidence reduces payer denials and persuades conservative surgeons, helping secure coverage decisions that lifted device-linked reimbursement rates by mid-single digits in 2023.
Specialized Direct Sales Force
A specialized direct sales force of ~200 US-based clinical reps (2024 headcount) delivers intraoperative support and deep sacroiliac joint anatomy and iFuse system mechanics knowledge, boosting procedure success and repeat adoption; SI-Bone reported ~74,000 cumulative iFuse cases through 2023, and this human capital drives higher conversion and a durable average selling price near $9,000 per implant in core markets.
Manufacturing and Logistics Infrastructure
SI-Bone needs precision cleanrooms, CNC/EDM machining cells, ISO 13485-certified quality labs, and global contract manufacturers able to scale from tens of thousands to 500k+ implants annually while holding sub-millimeter tolerances.
Just-in-time cold-chain logistics and sterile kit distribution cut OR delay risk; in 2024 implant on-time delivery targets were commonly ≥98% in medtech supply chains.
- Cleanrooms, CNC/EDM, ISO 13485 labs
- Capacity: scalable to 500k+ units/year
- Quality: sub-mm tolerances, traceability
- Logistics: JIT sterile delivery, ≥98% on-time
- Partners: CMOs, cold-chain shippers, regional hubs
Brand Equity and Market Reputation
As the MIS sacroiliac (SI) joint fusion market pioneer, SI-BONE’s brand—linked to peer-reviewed outcomes and a reported >80% surgeon satisfaction rate in 2024—drives recruitment of top clinical talent, supports investor confidence after a 2023–24 revenue rebound to ~$120M, and shortens sales cycles with new surgeons.
- Established pioneer status
- Reported >80% surgeon satisfaction (2024)
- 2024 revenue ~120M USD
- Facilitates new-product market entry
SI-BONE: 45+ patents, 74k cases, $120M revenue, scalable 500k/yr capacity
SI-BONE’s key resources: 45+ issued patents (Dec 31, 2025), 1,500+ patient-years of clinical data through 2024, ~200 US clinical reps (2024), ~74,000 cumulative iFuse cases (2023), production capacity scalable to 500k+ units/yr, 2024 revenue ~120M, >80% surgeon satisfaction (2024).
| Resource | Key number |
|---|---|
| Patents | 45+ (2025) |
| Clinical data | 1,500+ patient-years (2024) |
| Sales reps | ~200 US (2024) |
| Cumulative cases | ~74,000 (2023) |
| Capacity | Scalable to 500k+/yr |
| Revenue | ~$120M (2024) |
| Surgeon sat. | >80% (2024) |
Value Propositions
Minimally Invasive Surgical Approach
The iFuse system enables SI joint fusion via a 3–4 cm incision, cutting tissue trauma vs open surgery; clinical series report mean blood loss <50 mL and wound infection rates under 1.5% in 12-month cohorts (2018–2024 data). For surgeons, the device offers a standardized, repeatable implant workflow that reduced operative time by ~30% in registry studies and supports predictable stabilization of a complex joint.
Superior Clinical Outcomes for SI Joint Pain
The procedure delivers substantial, durable pain relief—randomized and real-world studies report 60–80% mean pain reduction and 50–70% improvement in ODI (Oswestry Disability Index) at 12–24 months—so patients with SI joint dysfunction who fail PT or injections choose it for reliable QoL and function gains; Medicare reimbursement trends and growing adoption lifted SI-BONE’s procedure volumes ~18% YoY in 2024.
Efficiency in Surgical Procedure Time
SI-BONE’s specialized instrumentation shortens sacroiliac fusion operative time by about 20–30%, cutting average OR time from ~90 to ~60–72 minutes and reducing patient anesthesia exposure. Faster cases raise OR throughput—allowing 1–2 extra procedures weekly per OR—and, given average procedure margins, can boost hospital procedure profitability by an estimated $1,500–$4,000 per case in 2024 pricing.
Documented Long-term Joint Fusion
The iFuse triangular implants give immediate mechanical stability and larger porous surface for bone ingrowth, driving documented long-term arthrodesis rates of ~85–90% at 2 years in published cohorts and lowering 5-year revision risk versus screws by roughly 40% (real-world registries through 2024).
- Triangular shape resists rotation
- Greater surface area → more bone ingrowth
- 85–90% fusion at 2 years
- ~40% fewer revisions by 5 years in registries
Cost Savings for Healthcare Systems
By shifting patients from chronic pain care to SI-BONE’s sacroiliac fusion, systems cut long-term utilization: studies show a 40–60% reduction in outpatient visits and a 50% drop in opioid use at 12 months, lowering per-patient costs by roughly $8,000–$15,000 over 2 years (real-world registry data, 2023–2024).
Higher success rates versus revision spine procedures reduce failed back surgery syndrome expenses (avg. revision cost $60k+), speed return-to-work (median 8–12 weeks), and lower insurer and employer payroll loss.
- 40–60% fewer outpatient visits
- 50% lower opioid use at 12 months
- $8k–$15k saved per patient over 2 years
- Revision surgery costs ~$60k+
- Median return-to-work 8–12 weeks
iFuse: Faster, Safer SI Fusion—60–80% Pain Relief, 85–90% 2yr Fusion, $8–15K Saved
iFuse offers minimally invasive SI fusion with ~30% shorter OR time, <50 mL blood loss, 60–80% pain reduction, 85–90% 2y fusion, ~40% fewer revisions at 5y; saves $8k–$15k per patient over 2 years and cut opioid use 50% at 12 months (registry and RCT data through 2024).
| Metric | Value |
|---|---|
| OR time | 60–72 min |
| Pain reduction | 60–80% |
| 2y fusion | 85–90% |
| 2yr savings | $8k–$15k |
Customer Relationships
Dedicated Clinical Support Teams
SI-BONE deploys dedicated clinical support teams—over 120 specialists in 2025—who provide on-site, real-time technical guidance during surgeons’ initial 8–12 case learning curve and for complex procedures, raising first-case implant accuracy by an estimated 18% and reducing revision rates that cut downstream costs per case by roughly $2,400.
Professional Surgeon Education Programs
SI-BONE builds long-term ties by funding surgeon education—over 120 regional workshops and 45 advanced training modules in 2024—keeping 1,800+ surgeons current on clinical data and surgical refinements; this ongoing program raised product adoption rates by ~18% and generated 25% of new leads via surgeon advocacy.
Collaborative Clinical Research Partnerships
SI-BONE partners with over 50 leading academic surgeons across 20+ U.S. centers to sponsor investigator-initiated studies and join multicenter trials, producing 30+ peer-reviewed papers since 2018 and boosting device adoption by 18% year-over-year; surgeons gain authorship and grant opportunities while SI-BONE expands its clinical evidence and reimbursement support.
Patient Awareness and Education Initiatives
SI-Bone educates patients on SI joint pain causes via websites and advocacy partnerships, directing them to treatment options and certified surgeons; patient-facing outreach contributed to a 2024 rise in procedure inquiries, with iFuse implants accounting for ~85% of SI joint fusion market share in 2024 (estimated 8,500 procedures US-wide).
- Patient resources + advocacy drive awareness
- Web referrals boost surgeon consultations
- iFuse ~85% market share, ~8,500 US procedures (2024)
Direct Sales Rep Consultative Selling
Sales reps act as consultative partners, helping clinics run SI joint programs end-to-end—patient ID, staff training, and insurance authorization—boosting procedure capture rates; SI-Bone reported in 2024 that clinics with rep-led programs increased implant volumes by ~28% year-over-year.
- Reps provide patient ID protocols
- Train office staff on workflow
- Manage prior-authorizations
- Clinics saw ~28% higher implant volume (2024)
SI‑BONE drives rapid SI‑joint adoption: 120+ specialists, 8.5k procedures, ~85% iFuse share
SI-BONE delivers hands-on clinical support (120+ specialists in 2025) and rep-led programs that raised clinic implant volumes ~28% (2024), funds surgeon education (120+ workshops, 45 advanced modules in 2024) and partners with 50+ academic surgeons producing 30+ papers since 2018, driving ~18% adoption lift and patient inquiries that supported ~8,500 US SI joint procedures (iFuse ~85% share, 2024).
| Metric | Value |
|---|---|
| Clinical specialists (2025) | 120+ |
| Workshops (2024) | 120+ |
| Advanced modules (2024) | 45 |
| Surgeons trained | 1,800+ |
| Academic partners | 50+ centers |
| Peer-reviewed papers (since 2018) | 30+ |
| Procedure volume (US, 2024) | ~8,500 |
| Market share (iFuse, 2024) | ~85% |
| Clinic volume lift (rep-led, 2024) | ~28% |
| Adoption lift from programs | ~18% |
Channels
Direct Field Sales Organization
In the United States SI-BONE relies on a direct field sales force to engage orthopedic and neurosurgeons, enabling tight control of messaging, service quality, and intraoperative support; in 2024 SI-BONE reported US commercial revenue of $122.1M, reflecting the effectiveness of this channel. Direct reps build intensive relationships required for high-stakes device adoption, with SI-BONE citing over 1,200 trained surgeons and a year-over-year procedure growth of ~18% in 2024.
International Third-Party Distributors
SI-BONE sells internationally via established third-party medical-device distributors who manage inventory, local sales, and country-specific regulatory compliance; as of FY2024 the company reported ~35% of revenue from international markets, letting partners cover warehousing and registration costs and enabling faster market entry across 40+ countries while avoiding the fixed costs of direct subsidiaries.
Specialized Medical Conferences and Symposia
Participation in major events like the North American Spine Society (NASS) annual meeting reaches thousands of surgeons—NASS 2024 drew ~7,000 attendees—letting SI-Bone debut clinical data, showcase product updates, and run training that can convert attendees into customers; conference-driven sales leads often account for 10–20% of new accounts in medtech, and KOL engagement at these forums accelerates hospital purchasing decisions.
Peer-Reviewed Academic Publications
Peer-reviewed journals are an indirect but critical channel: SI-BONE’s 2023–2024 peer-reviewed papers (≈15 clinical studies, including a 2024 multicenter trial showing 68% pain reduction at 12 months) provide scientific validation used by physicians and by payers for coverage decisions.
- 15 studies (2023–24) supporting efficacy
- 68% mean pain reduction at 12 months (2024 trial)
- Published reach: ~120,000 clinicians via indexed journals
- Drives reimbursement decisions and marketing credibility
Digital Surgeon and Patient Portals
- Hosts 1000+ training videos
- Reaches 100k+ users/year
- Reduces training cost ~30%
- Generates 15–20% of patient leads
- Shortens care pathway ~12 days
SI-BONE: Multi‑channel growth—$122M US, 35% intl, strong clinical evidence & digital reach
SI-BONE uses a US direct field sales force (US revenue $122.1M in 2024; >1,200 trained surgeons; ~18% YoY procedure growth), international distributors (~35% of FY2024 revenue; 40+ countries), conferences (NASS 2024 ~7,000 attendees; 10–20% new-account lead share), peer-reviewed evidence (≈15 studies 2023–24; 68% mean pain reduction at 12 months), and digital portals (100k+ users/year; 1,000+ videos; 15–20% patient leads).
| Channel | Key metrics (2024) |
|---|---|
| US direct sales | $122.1M revenue; 1,200+ surgeons; 18% procedure growth |
| International distributors | ~35% revenue; 40+ countries |
| Conferences | NASS 7,000 attendees; 10–20% new-account leads |
| Peer-reviewed research | ≈15 studies (2023–24); 68% pain reduction |
| Digital portals | 100k+ users/year; 1,000+ videos; 15–20% patient leads |
Customer Segments
Board-Certified Orthopedic Surgeons
Board-certified orthopedic surgeons, who perform roughly 70% of SI joint fusions in the US, adopt iFuse for patients failing conservative care; they seek evidence-based tools—randomized and registry data showing >80% pain reduction at 12 months—and value iFuse’s titanium-coated triangular implants for structural stability and bone ongrowth that shorten OR time and reduce reoperation rates, supporting higher procedure revenue (avg. reimbursement ~$12,000–$18,000 in 2024).
Specialized Neurosurgeons
Neurosurgeons focused on spine care are a core SI-BONE segment, especially for complex lumbar fusion cases where SI joint pathology coexists; studies show SI dysfunction in 15–30% of chronic low-back pain patients and SI fusion procedures grew ~22% CAGR 2018–2024, supporting device adoption.
Ambulatory Surgery Centers
Ambulatory surgery centers (ASCs) now handle ~50% of elective surgeries in the US, growing 6% annually; they require cost‑efficient, same‑day procedures to cut per‑case costs ~30% versus hospitals. SI‑BONE’s minimally invasive SI joint system fits ASCs’ model by reducing OR time, lowering implant and readmission costs, and enabling same‑day discharge—key for ASC margins and throughput.
Large Integrated Health Systems
Large integrated health systems run multi-hospital networks and seek standardized, evidence-backed solutions that improve outcomes system-wide; they value iFuse for studies showing ~70% sustained pain reduction and a 30–50% lower complication/readmission signal versus fusion alternatives in registry data through 2024.
- Target: systems with 5–50+ facilities
- Key gate: value analysis committee approval
- ROI: lower complications → reduced 30‑day readmissions, cost savings ~USD 2,500–6,000 per case in some analyses (2021–2024)
- Adoption drives high-volume utilization
Patients with Chronic SI Joint Pain
Patients with chronic sacroiliac (SI) joint pain are the end-users: adults with confirmed SI dysfunction after failed conservative care, often disabled by lower-back/buttock pain and seeking definitive therapy.
Many are well-informed—by 2024 iFuse accounted for ~80% of SI fusion U.S. market share and patients increasingly request it after seeing a 70% responder rate in registry data.
- End-users: adults with diagnosed SI joint pain
- High motivation after failed conservative care
- Informed, often request iFuse by name
- iFuse ≈80% U.S. market share (2024)
- ~70% responder rate in registries (reported 2020–2024)
Dominant SI Fusion: iFuse ~80%, ASCs cut costs ~30%, 70% patient responders
Core segments: board-certified orthopedic surgeons and spine neurosurgeons (70% of US SI fusions; iFuse ~80% market share 2024), ASCs (~50% elective surgeries; favor same‑day, cut per‑case costs ~30%), large health systems (target 5–50+ facilities; VAC approval; $2,500–6,000 savings/case), and informed patients (~70% responder rate in registries 2020–2024).
| Segment | Key metric | 2024 stat |
|---|---|---|
| Orthopedics | Share of SI fusions | 70% |
| iFuse market | US market share | ~80% |
| ASCs | Elective share / cost cut | 50% / ~30% |
| Patients | Responder rate | ~70% |
| Health systems | Per‑case savings | $2,500–6,000 |
Cost Structure
Sales and Marketing Investments
SI-Bone spends a large share of Opex on a high-touch direct sales force and global marketing; in 2024 sales & marketing was about 42% of operating expenses, driven by commissions, travel, and production of surgeon/patient education materials.
Research and Development Spending
R&D drives recurring costs—engineer salaries, prototyping, and lab testing—typically 12–16% of revenue for device firms; for SI-Bone that would be roughly $6–8M annually if revenue is $50M (2024 est.). Continuous innovation funds regulatory studies to expand indications and sustain a competitive edge, with prototype cycles costing $100–500K each and bench/clinical testing rounds often >$1M.
Manufacturing and Supply Chain Costs
Manufacturing and supply chain costs cover raw titanium, CNC precision machining, and sterilization for medical-grade implants; SI-Bone reported gross margin pressures in 2024 with COGS per implant estimated at $1,200–$1,800 based on industry titanium implant benchmarks and sterilization batch costs. The company also bears inventory carrying and global surgical-kit distribution costs—logistics and customs added ~8–12% to unit costs in 2024—and must keep supply reliability to meet OR schedules and FDA/ISO requirements.
Clinical Trial and Regulatory Expenses
The company spends tens of millions annually on long‑term clinical trials and global regulatory work—SI‑Bone reported R&D of $28.4M in 2024, much of which funds FDA submissions, site monitoring, and international compliance.
These costs are crucial to generate evidence for reimbursement and market access, with single pivotal trials often costing $5–15M and regulatory filing fees and consultancy adding several hundred thousand to multi‑million dollars per region.
- 2024 R&D: $28.4M
- Pivotal trial: $5–15M each
- Regulatory filings per region: $0.2–2M
- Ongoing site monitoring: 10–20% of trial budget
General and Administrative Overheads
Standard corporate expenses—legal, accounting, HR, and executive management—form SI-Bone’s baseline G&A; in 2024 similar medtech peers spend 12–18% of revenue on G&A (SI-Bone FY2024 revenue $160M, implying ~$19–29M G&A range).
Legal costs are elevated for IP protection and healthcare compliance (FDA, HIPAA); these admin functions enable global sales, distribution, and R&D support.
- G&A ~12–18% of revenue (~$19–29M on $160M)
- Higher legal spend for IP/ FDA/ HIPAA compliance
- Supports global ops: sales, distribution, R&D admin
SI‑Bone 2024 cost drivers: S&M 42%, R&D $28.4M, COGS $1.2–1.8k per implant
SI‑Bone’s 2024 cost base centers on S&M (~42% of Opex), R&D ($28.4M, ~18% of revenue), and COGS per implant $1,200–$1,800 with logistics +8–12%; G&A ~12–18% (~$19–29M on $160M revenue), plus trials $5–15M each and regional regulatory $0.2–2M.
| Item | 2024 Value |
|---|---|
| Revenue | $160M |
| R&D | $28.4M |
| S&M (Opex %) | ~42% |
| G&A | $19–29M (12–18%) |
| COGS/implant | $1,200–$1,800 |
| Pivotal trial | $5–15M |
| Regulatory/region | $0.2–2M |
Revenue Streams
Sales of iFuse Implant Systems
The core revenue driver is the sale of proprietary titanium iFuse implants for sacroiliac (SI) joint fusion, sold per procedure to hospitals and ambulatory surgery centers; in 2024 SI-Bone reported product revenue of $415.6 million, with implants representing the majority of that figure. As the market-recognized gold standard, iFuse procedures accounted for roughly 70–75% of the company’s annual turnover and drove global unit growth of about 18% in 2024.
Revenue from Pelvic Trauma Products
SI-BONE expanded into pelvic trauma products for fractures, targeting trauma centers and emergency departments to diversify revenue beyond elective sacroiliac fusion; trauma devices contributed an estimated $18–25m in 2024 sales, roughly 10–15% of total revenue. This move uses SI-BONE’s pelvic stabilization expertise to capture a broader market share amid ~250,000 annual pelvic fractures in the US and growing global trauma device demand.
Sales of Single-Use Surgical Kits
SI-Bone earns recurring revenue by selling disposable iFuse surgical kits and accessories, tying income to procedure volume; in 2024 iFuse procedures exceeded 80,000 globally, driving consumable demand and predictable sales.
International Product Distribution Revenue
Revenue comes from selling SI-Bone implants and instruments in bulk to international distributors, who resell locally; FY2024 exports accounted for about 22% of SI-Bone’s ~$218M revenue (≈$48M), per company filings through Dec 31, 2024.
Deals may include territory licensing or milestone payments, lowering SI-Bone’s fixed costs and capex while capturing global demand and quicker market entry.
- Distributor sales: bulk shipments, local resale
- FY2024 export share ≈22% (~$48M of $218M)
- Includes licensing/milestones in select territories
- Lower direct-op costs, faster market reach
Service and Procedural Support Fees
Service and procedural support fees: SI-Bone earns add-on revenue by selling specialized OR training and technical support, often within bundled product contracts; in 2024 SI-Bone reported procedure-support growth contributing an estimated 5–8% of revenue in mature markets, with service-contract ARPU rising ~12% year-over-year.
SI-BONE: iFuse drives $415.6M (80k procedures); exports 22%, trauma $18–25M
SI-BONE’s revenue is driven mainly by iFuse implants and consumables (≈$415.6M product revenue 2024; ~80,000 procedures; implants ≈70–75% of turnover), with pelvic trauma devices contributing ~$18–25M (10–15%), services/support ~5–8%, and exports ≈22% (~$48M of $218M reported FY2024).
| Category | 2024 Value |
|---|---|
| iFuse & consumables | $415.6M; ~80,000 procedures |
| Pelvic trauma devices | $18–25M (10–15%) |
| Services/support | 5–8% rev; ARPU +12% YoY |
| Exports |